Fewer Than Half of U.S. Pharmacies Carry One of the Most Effective Drugs for Opioid Abuse

A pharmacist holding a box of medication.
June 13, 2022
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.

PharmE3D Labs Receive Federal Funding for 3D Printed Contraception

Four people wearing masks and lab coats.
March 14, 2022
Dr. Mo Maniruzzaman's Pharmaceutical Engineering and 3D Printing Labs have received a federal grant from the United States Agency for International Development (USAID) to develop personalized 3D printed non-hormonal intrauterine devices (IUDs). The project’s goal is to increase global access to long-term and effective contraception while minimizing some of its most debilitating side effects.

Moczygemba and Wash Earn 2022 Kloesel Grant

A woman and a man smiling.
January 11, 2022
Leticia "Tish" Moczygemba, Pharm.D., Ph.D. and Andrew Wash, Pharm.D. were selected as the recipients of the 2022 grant award from the Arlyn Kloesel Endowment for Excellence in Pharmacy Practice.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

PharmE3D Labs Receive R01 Grant for Complex Vaccine Technologies

Three people smiling.
September 24, 2021
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.

PharmE3D Labs Earn Multiple Pharmaceutical Science Distinctions

Three men smiling.
September 10, 2021
The college's Pharmaceutical Engineering and 3D Printing (PharmE3D) labs, led by Assistant Professor in Molecular Pharmaceutics and Drug Delivery Mohammed (Mo) Maniruzzaman, Ph.D., has recently earned several national and international awards and scholarships for outstanding research contributions to the field of pharmaceutical science and technology.

Vasquez Appears on BBC World Service to Discuss Z-DNA

DNA.
June 16, 2021
Division Head and Professor of Pharmacology and Toxicology Karen Vasquez, Ph.D. appeared on BBC World Service's Science in Action to talk about Z-DNA. Dr. Vasquez's research focuses on DNA damage and repair, genomic instability, gene targeting, DNA structure and cancer therapeutics.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

Fight Against Antibiotic-Resistant Bacteria Has a Glowing New Weapon

A 3D representation of the chemical probe as it bridges two zinc molecules
June 2, 2021
Chemistry Assistant Professor Emily Que, Ph.D. and the College of Pharmacy’s Walt Fast, Ph.D. are working together to research new methods to fight against antibiotic resistance. The fluorescent chemical probe developed by Que and Fast may help find a different way to combat resistant bacteria.

Maniruzzaman Lab Earns Grant to Research 3D Printed COVID-19 Treatment

A man holding up a dish in a lab.
May 26, 2021
The UT College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab earned a Texas Global Faculty Research Seed Grant for its work on patient-specific treatment of COVID-19.